# US 2008/0306053 A1 · Modulation of chemosensory receptors and ligands associated therewith

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306053 A1
- Document ID: US20080306053A1
- Status: Published application
- Kind: A1
- Application number: 11/836,074
- Filed: 2007-08-08
- Published: 2008-12-11
- Earliest claimed: 2007-06-08
- Assignees: Senomyx, Inc.
- Inventors: Catherine Tachdjian; Xiao-Qing Tang; Sara Werner; Marketa Rinnova; Qing Chen; Guy Servant; Xiaodong Li; Feng Zhang; Haitian Liu; Albert Zlotnik; Mark Zoller; Boris Klebansky; Richard Fine; Xinshan Kang
- Web page: https://patentgrep.com/patent/US20080306053A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A23L 2/39: Dry compositions
- A23L 2/60: Sweeteners
- A23L 27/30: Artificial sweetening agents
- A23L 27/31: {containing amino acids, nucleotides, peptides or derivatives}
- A23L 27/33: {containing sugars or derivatives}
- A23L 27/34: {Sugar alcohols}
- A23L 27/88: {Taste or flavour enhancing agents}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 13/10: of the bladder
- A61P 27/00: Drugs for disorders of the senses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 215/42: attached in position 4
- C07D 215/54: attached in position 3
- C07D 215/56: with oxygen atoms in position 4
- C07D 239/70: condensed with carbocyclic rings or ring systems
- C07D 239/84: Nitrogen atoms
- C07D 239/94: Nitrogen atoms
- C07D 239/95: with hetero atoms directly attached in positions 2 and 4
- C07D 285/16: Thiadiazines; Hydrogenated thiadiazines
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/04: Ortho-condensed systems
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 493/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 495/14: Ortho-condensed systems
- C07D 513/20: Spiro-condensed systems
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, wherein A is —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11.

### Claim at position 3

5-8. (canceled)

### Claim 9 (depends on 1)

The compound of claim 1, wherein A is —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11 and R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1 of structural Formula (IIb):
wherein:
W is —C(R24)— or —N—;
Y is —C(R26)— or —N—; and
Z is —S—, —N(R28)— or —O—.

### Claim 12 (depends on 11)

The compound of claim 11, wherein W is —C(R24)—, Y is —C(R26)— and Z is —S—, —N(R28)— or —O—.

### Claim 13 (depends on 11)

The compound of claim 11, wherein R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR29, —S(O)gR29, —OCOR29, —NR29R30, —CONR29R30 or —CO2R29 and R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —OCOR31, —S(O)hR31, —NR31R32, —CONR31R32 or —CO2R31.

### Claim 14 (depends on 11)

The compound of claim 11, wherein R24 is hydrogen, —CF3, alkyl or substituted alkyl and R26 is hydrogen, —CF3, alkyl or substituted alkyl.

### Claim 15 (depends on 11)

The compound of claim 11, wherein A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, —CN, —NO2, —S(O)cR9, —NR9R10, —CONR9R10, —CO2R9 or —NR9CO2R10, R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, OR29, —S(O)gR29, —OCOR29, —NR29R30, —CONR29R30 or —CO2R29 and R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32 or —CO2R31.

### Claim 16 (depends on 11)

The compound of claim 11, wherein A is —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11 and R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, R24 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR29, —S(O)gR29, OCOR29, —NR29R30, —CONR29R30 or —CO2R29 and R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32 or —CO2R31.

### Claim 17 (depends on 11)

The compound of claim 11, wherein A is —OH, —NH2, —NHCH3, —N(CH3)2, —NHOCH3, —NOCH3, —NHC(O)CH3, —NHC(O)OCH3, —NHC(O)NH2, —NHC(S)NH2, —NHC(NH)NH2, —CN, —CH2OH, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2, —CO2H, —CONH2, —CONHCH3 or —CH2NHC(O)CH3, R17 is hydrogen, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, phenyl or benzyl, R24 is hydrogen, —CF3, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or t-butyl and R26 is hydrogen, —CF3, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or t-butyl.

### Claim 18 (depends on 11)

The compound of claim 11, wherein A is —NH2, R17 is hydrogen or methyl, R24 is hydrogen, —CF3, methyl or ethyl and R26 is hydrogen, —CF3, methyl or ethyl.

### Claim 19 (depends on 12)

The compound of claim 12, wherein A is —NH2, R17 is hydrogen or methyl, R24 is hydrogen, —CF3, methyl or ethyl and R26 is hydrogen, —CF3, methyl or ethyl.

### Claim 20 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 11-19, wherein R28 is hydrogen, alkyl or arylalkyl.

### Claim 21 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 11-19, wherein R28 is hydrogen, methyl or benzyl.

### Claim 22 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 11-19, wherein Z is S.

### Claim at position 18

23-27. (canceled)

### Claim 28 (depends on 23)

The compound of claim 23, wherein A —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11 and R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl, R27 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR33, —S(O)iR33, —OCOR33, —NR33R34, —CONR33R34 or —CO2R33 and R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32 or —CO2R31.

### Claim at position 20

29-31. (canceled)

### Claim 32 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 23-31, wherein R25 is hydrogen, alkyl or arylalkyl.

### Claim 33 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 23-31, wherein R25 is hydrogen, methyl or benzyl.

### Claim 34 (depends on 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of anyone of claims 23-31, wherein Z is S.

### Claim 35 (depends on 1)

The compound of claim 1 having the structure:

### Claim 36 (depends on 1)

The compound of claim 1 having the structure:
wherein R12 is —OH, —SH, —CN, —CH2OH, —CO2R13 or —CONR13R14.

### Claim 37 (depends on 1)

The compound of claim 1 having the structure:

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The compound of claim 1 having the structure:

### Claim 40 (depends on 1)

The compound of claim 1 having the structure:

### Claim 41

A compound of structural Formula (IIIa):
or a salt, hydrate, solvate or N-oxide thereof wherein:
A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, halo, —CN, —NO2, —OR9, —S(O)cR9, —NR9R10, —NOR9, —NHOR9, —CONR9R10, —CO2R9, —NR9COR10, —NR9CO2R10, —NR9CONR10R11, —NR9CSNR10R11, —NR9C(═NH)NR10R11, —B(OR10)(OR11), —P(O)(OR10)(OR11) or —P(O)(R10)(OR11);
R17 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or —CO2R19;
B is —N— or
R12 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, —NR13R14, —CN, —OR13, —S(O)dR13, —CO2R13 or —CONR13R14;
H is —C(R35)— or —N—;
I is —C(R36) or —N—;
J is —C(R37)— or —N—;
K is —C(R38)— or —N—;
R35 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, halo, chloro, fluoro, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, —CN, —NO2, —OR39, —S(O)iR39, —OCOR39, —NR39COR40, —CONR39R40, —CO2R39, —SO2NR39R40, —NR39SO2R40, —B(OR39)(OR40), —P(O)(OR39)(OR40); or
R36 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, halo, chloro, fluoro, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, —CN, —NO2, —OR41, —S(O)kR41, —OCOR41, —NR41COR42, —NR41R42, —CONR41R42, —CO2R41, —SO2NR41R42, —NR41SO2R42, —B(OR41)(OR42), —P(O)(OR41)(OR42) or —P(O)(R41)(OR42);
R37 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, halo, chloro, fluoro, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl ,—CN, —NO2, —OR43, —S(O)1R43, —OCOR43, —NR43R44, —CONR43R44, —CO2R43, —SO2NR43R44, —NR43SO2R44, —B(OR43)(OR44), —P(O)(OR43)(OR44) or —P(O)(R43)(OR44);
R38 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, halo, chloro, fluoro, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, —CN, —NO2, —OR45, —S(O)mR45, OCOR45, —NR45COR46, —NR45R46, —CONR45R46, —CO2R45, SO2NR45R46, —NR45SO2R46, —B(OR45)(OR46), —P(O)(OR45)(OR46) or —P(O)(R45)(OR46);
c, d, j, k, 1 and m are independently 0, 1 or 2; and
R9, R13, R14, R19 and R39-R46 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl or alternatively R13 and R14, R39 and R40, R41 and R42, R43 and R44 and R45 and R46 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring;
with the proviso that at most, three of H, I, J and K are —N—.

### Claim 42 (depends on 41)

The compound of claim 41, wherein none of H, I, J, K are —N—.

### Claim 43 (depends on 41)

The compound of claim 41, wherein A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, —CN, —NO2, —S(O)cR9, —NR9COR10, —NR9R10, —CONR9R10, —CO2R9 or —NR9CO2R10.

### Claim 44 (depends on 41)

The compound of claim 41, wherein A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, —CN, —NO2, —S(O)cR9, —NR9R10, —CONR9R10, —CO2R9, —NR9COR10 or —NR9CO2R10.

### Claim 45 (depends on 39)

The compound of claim 39, wherein A is —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11.

### Claim 46 (depends on 41)

The compound of claim 41, wherein A is —OH, —NH2, —NHCH3, —N(CH3)2, —NHOCH3, —NOCH3, —NHC(O)CH3, —NHC(O)OCH3, —NHC(O)NH2, —NHC(S)NH2, —NHC(NH)NH2, —CN, —CH2OH, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2, —CO2H, —CONH2, —CONHCH3 or —CH2NHC(O)CH3.

### Claim 47 (depends on 41)

The compound of claim 41, wherein R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl.

### Claim 48 (depends on 41)

The compound of claim 41, wherein R17is hydrogen, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, phenyl or benzyl.

### Claim 49 (depends on 41)

The compound of claim 41, wherein A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, —CN, —NO2, —S(O)cR9, —NR9R10, —CONR9R10, —CO2R9 or —NR9CO2R10 and R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl.

### Claim 50 (depends on 41)

The compound of claim 41, wherein A is —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11 and R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl.

### Claim 51 (depends on 41)

The compound of claim 41, wherein A is —OH, —NH2, —NHCH3, —N(CH3)2, —NHOCH3, —NOCH3, —NHC(O)CH3, —NHC(O)OCH3, —NHC(O)NH2, —NHC(S)NH2, —NHC(NH)NH2, —CN, —CH2OH, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2, —CO2H, —CONH2, —CONHCH3 or —CH2NHC(O)CH3 and R17 is hydrogen, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, phenyl or benzyl.

### Claim 52 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 41-51, wherein R35 is hydrogen, —OH, —NR39R40, —NR39COR40, —OCOR39, —CF3, —OCF3, —OCH3, —OC2H5, —OC3H7, —CH3, —C2H5, —CH(CH3)2, chloro, fluoro, —CH2OH, —CH2OCH3, —CN, —C(O)NR39R40, —CO2R40, SO2NR39R40, —NR39SO2R40, —B(OR39)(OR40), —P(O)(OR39)(OR40) or —P(O)(R39)(OR40);
R36 is hydrogen, —OH, —NR41R42, —NR41COR42, —OCOR41, —CF3, —OCF3, —OH, —OCH3, —OC2H5, —OC3H7, —CH3, —C2H5, —CH(CH3)2, chloro, fluoro, —CH2OH, —CH2OCH3, —CN, —C(O)NR41R42, —CO2R41, —SO2NR41R42, —NR41SO2R42, —B(OR41)(OR42), —P(O)(OR41)(OR42) or —P(O)(R41)(OR42);
R37 is hydrogen, —OH, —NR43R44, —NR43COR44, —OCOR43, —CF3, —OCF3, OH, —OCH3, —OC2H5, —OC3H7, chloro, fluoro, —CH3, —C2H5, —CH(CH3)2, —CH2OH, —CH2OCH3, —CN, —C(O)NR43R44, —CO2R43, —SO2NR43R44, —NR43SO2R44, —B(OR43)(OR44), —P(O)(OR43)(OR44) or —P(O)(R43)(OR44); and
R38 is hydrogen, —OH, —NR45R46, —NR45COR46, —OCOR45, —CF3, —OCF3, —OH, —OCH3, —OC2H5, —OC3H7, —CH3, —C2H5, —CH(CH3)2, chloro, fluoro, —CH2OH, —CH2OCH3, —CN, —C(O)NR45R46, —CO2R45, —SO2NR45R46, —NR45SO2R46, —B(OR45)(OR46), —P(O)(OR45)(OR46) or —P(O)(R45)(OR46).

### Claim 53 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 41-51, wherein R35 is hydrogen, —OH, —OCH3, —OC2H5, —OC3H7, —CH3, —C2H5, —CH(CH3)2, chloro, fluoro, —CH2OH, —CH2OCH3, —CN, —C(O)NR39R40 or —CO2R40;
R36 is hydrogen, —OH, —OCH3, —OC2H5, —OC3H7, —CH3, —C2H5, —CH(CH3)2, chloro, fluoro, —CH2OH, —CH2OCH3, —CN, —C(O)NR41R42 or —CO2R41;
R37 is hydrogen, —OH, —OCH3, —OC2H5, —OC3H7, chloro, fluoro, —CH3, —C2H5, —CH(CH3)2, —CH2OH, —CH2OCH3, —CN, —C(O)NR43R44, or —CO2R43; and
R38 is hydrogen, —OH, —OCH3, —OC2H5, —OC3H7, —CH3, —C2H5, —CH(CH3)2, chloro, fluoro, —CH2OH, —CH2OCH3, —CN, —C(O)NR45R♯or —CO2R45.

### Claim 54 (depends on 41)

The compound of claim 41, wherein A is —NH2, R17 is hydrogen, methyl, ethyl or benzyl R35, R36, R37 and R38 are independently hydrogen, methyl, —OH or OCH3.

### Claim 55 (depends on 41)

The compound of claim 41, A is —NH2, R17 is hydrogen, methyl, ethyl or benzyl and R35, R36, R37 and R38 are independently hydrogen, methyl, —OH or OCH3.

### Claim 56 (depends on 40)

The compound of claim 40, wherein A is —NH2, R17 is hydrogen or methyl, and R35, R36, R37 and R38 are independently hydrogen or methyl.

### Claim 57 (depends on 41)

The compound of claim 41, wherein A is —NH2, R17 is hydrogen or methyl, and R35, R36, R37 and R38 are independently hydrogen or methyl.

### Claim 58 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 54, 55, 56, 57)

The compound of any one of claims 41-51 and 54-57, wherein B is —N—.

### Claim 59 (depends on 41)

The compound of claim 41 having the structure:

### Claim 60 (depends on 41)

The compound of claim 41 having the structure:

### Claim 61 (depends on 41)

The compound of claim 41 having the structure:

### Claim at position 51

62-67. (canceled)

### Claim 68

A composition comprising
at least a sweet flavor entity; and
a compound of structural Formula (IIc):
or a salt thereof; wherein:
A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, —CN, —NO2, —OR9, —S(O)cR9, —NR COR9, —NHOR9, —NR9R10, —NOR9, —CONR9R10, —CO2R9, —NR9CO2R10, —NR9CONR10R11, —NR9CSNR10R11, —NR9C(═NH)NR10R11;
R17 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or —CO2R19;
Y forms a single bond with W and a double bond with Z;
W is —S—;
Y is —C(R26)—;
Z is —C(R27)—;
R26 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32, —CO2R31, —NR31COR32, —SO2NR31R32, —NR31SO2R32;
R27 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl —CN, —NO2, —OR33, —S(O)iR33, —OCOR33, —NR33R34, —CONR33R34, —CO2R33, —NR33COR34, —SO2NR33R34, —NR33SO2R33; or alternatively R26 and R27 together with the atoms to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;
c, h and i are independently 0 or 1 or 2;
R9 to R11, R19 and R31 to R34 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl; alternatively R10 and R11, R31 and R32, or R33 and R34 together with the atoms to which they are bonded form a cycloheteroalkyl or substituted cycloheteroalkyl ring.

### Claim at position 53

69-71. (canceled)

### Claim 72 (depends on 1, 41)

A method of enhancing the sweet taste of a comestible or medicinal product comprising contacting a comestible or medicinal product or precursors thereof with a compound of claim 1 or 41 to form a modified comestible or medicinal product, wherein the modified comestible or medicinal product comprises at least about 0.001 ppm of the compound.

### Claim 73 (depends on 72)

The method of claim 72 wherein the modified comestible or medicinal product comprises at least between about 0.001 ppm to about 100,000 ppm of the compound.

### Claim 74 (depends on 72)

The method of claim 72, wherein the comestible or medicinal product comprises sucralose.

### Claim 75 (depends on 1, 41)

A method of treating a condition associated with a chemosensory receptor comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1 or claim 41.

### Claim 76 (depends on 75)

The method of claim 75, wherein the compound interacts with an interacting site of the chemosensory receptor.

### Claim 77 (depends on 75)

The method of claim 75, wherein the condition associated with a chemosensory receptor is taste.

### Claim 78 (depends on 75)

The method of claim 75, wherein the condition associated with a chemosensory receptor is a condition associated with gastrointestinal system or metabolic disorders.

### Claim 79 (depends on 75)

The method of claim 75, wherein the condition associated with a chemosensory receptor is a condition associated with a functional gastrointestinal disorder.

### Claim 80 (depends on 75)

The method of claim 75, wherein the condition associated with a chemosensory receptor is a condition associated with cells expressing a T1R.

### Claim 81 (depends on 75)

The method of claim 75, wherein the condition associated with a chemosensory receptor is a condition associated with hormone-producing cells that express a T1R.

### Claim 82 (depends on 1, 41)

A method of modulating the activity of a chemosensory receptor ligand comprising contacting a chemosensory receptor ligand modifier with a cell containing T1R2 Venus flytrap domain in the presence of a chemosensory receptor ligand, wherein the chemosensory receptor ligand modifier interacts with an interacting site of the chemosensory receptor and wherein the chemosensory receptor ligand modifier is a compound of claim 1 or claim 41.

### Claim 83 (depends on 82)

The method of claim 82, wherein the interacting site of the chemosensory receptor includes an interacting residue selected from the group consisting of amino acid N 143, S 144, and I167 of a human T1R2 and a combination thereof.

### Claim 84 (depends on 82)

The method of claim 82, wherein the interacting site of the chemosensory receptor includes an interacting residue selected from the group consisting of amino acid S40, S144, S165, Y103, D142, and P277 of a human T1R2 and a combination thereof.

### Claim 85 (depends on 82)

The method of claim 82, wherein the interacting site of the chemosensory receptor includes an interacting residue selected from the group consisting of amino acid K65, R383, D307, E302, and D278 of a human T1R2 and a combination thereof.

### Claim 86 (depends on 82)

The method of claim 82, wherein the interacting site of the chemosensory receptor includes an interacting residue selected from the group consisting of amino acid I167, P185, T184, T326, E302, V384, A305, I325, I306, R383, D307, E382, D278, I279, I167V66, V309, D142, S165, S40, S303, T242, F103, Q328, and S168 of a human T1R2 and a combination thereof.

### Claim 87 (depends on 82)

The method of claim 82, wherein the interacting site includes an interacting residue selected from the group consisting of amino acid N143, S144, I167, S40, S144, S165, Y103, D142, P277, K65, R383, D307, E302, D278, P185, T184, T326, E302, V384, A305, I325, I306, D307, E382, I279, I67, V66, V309, S303, T242, F103, Q328, and S168 of a human T1R2 and a combination thereof.

### Claim 88 (depends on 82)

The method of claim 82, wherein the interacting site includes a group of interacting residues of K65, D278, L279, D307, R383, and V384 of a human T1R2 and wherein the chemosensory receptor ligand modifier enhances the activity of a chemosensory receptor ligand.

### Claim 89 (depends on 82)

The method of claim 82, wherein the interacting site includes a group of interacting residues of S40, S144, Y103, D142, and P277 of a human T1R2 and wherein the chemosensory receptor ligand is selected from the group consisting of sucrose and sucralose.

### Claim 90 (depends on 82)

The method of claim 82, wherein the chemosensory receptor ligand modifier stabilizes a close conformation within T1R2 Venus flytrap domain formed by the interaction between the chemosensory receptor ligand and the chemosensory receptor.

### Claim 91 (depends on 82)

The method of claim 82, wherein the cell contains T1R2 Venus flytrap domain within a GPCR pathway.

### Claim 92 (depends on 82)

The method of claim 82, wherein the compound is provided in a comestible composition.

### Claim 93 (depends on 82)

The method of claim 82, wherein the compound is provided in a medicinal composition.

### Claim 94 (depends on 82)

The method of claim 82, wherein the compound is provided in a food or beverage product.

### Claim 95 (depends on 82)

The method of claim 82, wherein the activity of the chemosensory receptor ligand is increased.

### Claim 96 (depends on 82)

The method of claim 82, wherein the chemosensory receptor ligand is sucralose.

### Claim 97 (depends on 68)

The composition of claim 68, wherein the sweet flavor entity is selected from the group consisting of cyclamic acid, mogroside, tagatose, maltose, galactose, mannose, sucrose, fructose, lactose, aspartame, neotame and other aspartame derivatives, saccharin, sucralose, acesulfame K, glucose, erythritol, D-tryptophan, glycine, mannitol, sorbitol, maltitol, lactitol, isomalt, hydroganeted glucose syrup (HGS), hydrogenated starch hydrolyzate (HSH), stevioside, rebaudioside A and other sweet Stevia-based glycosides, alitame, carrelame and other guanidine-based sweeteners, tagatose, xylitol, high fructose corn syrup, and combinations thereof.

### Claim 98 (depends on 68)

The composition of claim 68, wherein the sweet flavor entity is sucralose.

### Claim at position 81

99-100. (canceled)

### Claim 101 (depends on 68)

The composition of claim 68, wherein
R27 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR33, —S(O)iR33, —OCOR33, —NR33R34, —CONR33R34 or —CO2R33; and
R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32 or —CO2R31.

### Claim 102 (depends on 68)

The composition of claim 68, wherein
R27 is hydrogen, alkyl or substituted alkyl; and
R26 is hydrogen, alkyl or substituted alkyl.

### Claim 103 (depends on 68)

The composition of claim 68, wherein
A is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, —CN, —NO2, —S(O)cR9, —NR9R10, —CONR9R10, —CO2R9 or —NR9CO2R10;
R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl;
R27 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR33, —S(O)iR33, —OCOR33, —NR33R34, —CONR33R34 or —CO2R33; and
R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32or —CO2R31.

### Claim 104 (depends on 68)

The composition of claim 68, wherein
A —OR9, —NR9CONR10R11, —NR9CSNR10R11 or —NR9C(═NH)NR10R11;
R17 is hydrogen, alkyl, substituted alkyl, arylalkyl, or substituted arylalkyl;
R27 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR33, —S(O)iR33, —OCOR33, —NR33R34, —CONR33R34 or —CO2R33; and
R26 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, heteroalkyl, substituted heteroalkyl, —CN, —NO2, —OR31, —S(O)hR31, —OCOR31, —NR31R32, —CONR31R32or —CO2R31.

### Claim 105 (depends on 68)

The composition of claim 68, wherein
A is —OH, —NH2, —NHCH3, —N(CH3)2, —NHOCH3, —NOCH3, —NHC(O)CH3, —NHC(O)OCH3, —NHC(O)NH2, —NHC(S)NH2, —NHC(NH)NH2, —CN, —CH2OH, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2, —CO2H, —CONH2, —CONHCH3 or —CH2NHC(O)CH3;
R17 is hydrogen, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, phenyl or benzyl;
R27 is hydrogen, —CF3, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or t-butyl; and
R26 is hydrogen, —CF3, methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl or t-butyl.

### Claim 106 (depends on 68)

The composition of claim 68, wherein
A is —NH2;
R17 is hydrogen or methyl;
R27 is hydrogen, —CF3, methyl or ethyl; and
R26 is hydrogen, —CF3, methyl or ethyl.

### Claim 107 (depends on 99, 100, 101, 102, 103, 104, 105, 106)

The compound of any one of claims 99 to 106, wherein
R25 is hydrogen, alkyl or arylalkyl.

### Claim 108 (depends on 99, 100, 101, 102, 103, 104, 105, 106)

The compound of any one of claims 99 to 106, wherein
R25 is hydrogen, methyl or benzyl.

### Claim 109 (depends on 99, 100, 101, 102, 103, 104, 105, 106)

The compound of anyone of claims 99 to 106, wherein
Z is —S—.

### Claim 110 (depends on 99)

The comestible or medicinal composition of claim 99, wherein the compound of structural Formula (IIc) has a structural formula selected from the group consisting of

### Claim 111 (depends on 99)

The comestible or medicinal composition of claim 99, wherein the compound of structural Formula (IIc) has a structural formula selected from the group consisting of
wherein R12 is —OH, —SH, —CN, —CH2OH, —CO2R13 or —CONR13R14.

### Claim 112 (depends on 68)

The composition of claim 68, wherein the compound of structural Formula (IIc) has a structural formula selected from the group consisting of

### Claim 113 (depends on 68)

The composition of claim 68, comprising a hydrochloride salt of the compound of structural Formula (IIc) selected from the group consisting of

### Claim 114 (depends on 68)

The composition of claim 68, comprising between about 0.0001 ppm to about 10 ppm of the compound of structural Formula (IIc).

### Claim 115 (depends on 68)

The composition of claim 68, comprising between about 0.0001 ppm to about 100 ppm of the compound of structural Formula (IIc).

### Claim 116 (depends on 68)

The composition of claim 68, comprising between about 0.01 ppm to about 100 ppm of the compound of structural Formula (IIc).

### Claim 117 (depends on 68)

The composition of claim 68, comprising between about 10 ppm to about 100,000 ppm of the compound of structural Formula (IIc).

### Claim at position 99

118-119. (canceled)

### Claim 120 (depends on 68)

The composition of claim 68 is a food or beverage product.

### Claim 121 (depends on 120)

The composition of claim 120, wherein the food or beverage product is selected from the group consisting of the Wet Soup Category, the Dehydrated and Culinary Food Category, the Beverage Category, the Frozen Food Category, the Snack Food Category, seasonings or seasoning blends, and combinations thereof.

### Claim 122 (depends on 120)

The composition of claim 120, wherein the food or beverage product is selected from the group consisting of carbonated and non-carbonated beverages; fruit or vegetable juices; alcoholic and non-alcoholic beverages; confectionary products; cereal and breakfast foods; canned fruits and fruit sauces; sweet coatings, frostings, and glazes; and combinations thereof.

### Claim 123 (depends on 68)

The composition of claim 68, wherein
A is —NR9R10;
R17 is hydrogen, alkyl, or substituted alkyl,;
R27 is hydrogen, alkyl, or substituted alkyl;
R26 is hydrogen, alkyl, or substituted alkyl; and
R9 and R10 are each independently hydrogen, alkyl, or substituted alkyl.

### Claim 124 (depends on 68)

The composition of claim 68, which is a comestible or medicinal composition.

### Claim 125 (depends on 124)

The medicinal composition of claim 124, comprising a pharmaceutically acceptable vehicle.
